Literature DB >> 35895225

A Review of Causal Inference for External Comparator Arm Studies.

Gerd Rippin1, Nicolás Ballarini2, Héctor Sanz2, Joan Largent2, Chantal Quinten3, Francesco Pignatti3.   

Abstract

Randomized controlled trials (RCTs) are the gold standard design to establish the efficacy of new drugs and to support regulatory decision making. However, a marked increase in the submission of single-arm trials (SATs) has been observed in recent years, especially in the field of oncology due to the trend towards precision medicine contributing to the rise of new therapeutic interventions for rare diseases. SATs lack results for control patients, and information from external sources can be compiled to provide context for better interpretability of study results. External comparator arm (ECA) studies are defined as a clinical trial (most commonly a SAT) and an ECA of a comparable cohort of patients-commonly derived from real-world settings including registries, natural history studies, or medical records of routine care. This publication aims to provide a methodological overview, to sketch emergent best practice recommendations and to identify future methodological research topics. Specifically, existing scientific and regulatory guidance for ECA studies is reviewed and appropriate causal inference methods are discussed. Further topics include sample size considerations, use of estimands, handling of different data sources regarding differential baseline covariate definitions, differential endpoint measurements and timings. In addition, unique features of ECA studies are highlighted, specifically the opportunity to address bias caused by unmeasured ECA covariates, which are available in the SAT.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Year:  2022        PMID: 35895225     DOI: 10.1007/s40264-022-01206-y

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.228


  92 in total

1.  Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data.

Authors:  Steffen Ventz; Albert Lai; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Clin Cancer Res       Date:  2019-06-07       Impact factor: 12.531

2.  The role of nonrandomized trials in the evaluation of oncology drugs.

Authors:  R Simon; G M Blumenthal; M L Rothenberg; J Sommer; S A Roberts; D K Armstrong; L M LaVange; R Pazdur
Journal:  Clin Pharmacol Ther       Date:  2015-04-07       Impact factor: 6.875

Review 3.  External control arms in oncology: current use and future directions.

Authors:  P S Mishra-Kalyani; L Amiri Kordestani; D R Rivera; H Singh; A Ibrahim; R A DeClaro; Y Shen; S Tang; R Sridhara; P G Kluetz; J Concato; R Pazdur; J A Beaver
Journal:  Ann Oncol       Date:  2022-01-10       Impact factor: 32.976

4.  Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia.

Authors:  Anthony J Hatswell; Gwilym J Thompson; Penny A Maroudas; Oleg Sofrygin; Thomas E Delea
Journal:  Cost Eff Resour Alloc       Date:  2017-05-26

Review 5.  A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data.

Authors:  Christen M Gray; Fiona Grimson; Deborah Layton; Stuart Pocock; Joseph Kim
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606

6.  Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.

Authors:  Sarah Goring; Aliki Taylor; Kerstin Müller; Tina Jun Jian Li; Ellen E Korol; Adrian R Levy; Nick Freemantle
Journal:  BMJ Open       Date:  2019-02-27       Impact factor: 2.692

7.  Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms.

Authors:  Mehmet Burcu; Nancy A Dreyer; Jessica M Franklin; Michael D Blum; Cathy W Critchlow; Eleanor M Perfetto; Wei Zhou
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-03-11       Impact factor: 2.890

Review 8.  The Use of External Controls in FDA Regulatory Decision Making.

Authors:  Mahta Jahanshahi; Keith Gregg; Gillian Davis; Adora Ndu; Veronica Miller; Jerry Vockley; Cecile Ollivier; Tanja Franolic; Sharon Sakai
Journal:  Ther Innov Regul Sci       Date:  2021-05-20       Impact factor: 1.778

9.  Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable.

Authors:  Nancy A Dreyer
Journal:  Ther Innov Regul Sci       Date:  2018-03-19       Impact factor: 1.778

10.  The Future of Precision Medicine: Potential Impacts for Health Technology Assessment.

Authors:  James Love-Koh; Alison Peel; Juan Carlos Rejon-Parrilla; Kate Ennis; Rosemary Lovett; Andrea Manca; Anastasia Chalkidou; Hannah Wood; Matthew Taylor
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.